The Quiet Consolidation of Heart Care
Private equity has spent the better part of a decade absorbing dermatology groups, urgent care chains, and orthopedic practices. Cardiology held out longer – partly because of its clinical complexity, partly because cardiologists have historically enjoyed strong hospital employment arrangements that made independent practice less financially precarious. That window is closing. Across the South, Midwest, and mid-Atlantic states, cardiology groups with five to thirty physicians are signing letters of intent with PE-backed management companies, often without any public announcement and sometimes without their own junior partners fully understanding the terms until well after close.
The scale of this shift is not yet visible in headline M&A data, because most of these transactions fall below the thresholds that trigger regulatory scrutiny or press coverage. But the pattern is unmistakable to anyone watching practice brokerage activity or tracking which groups have quietly stopped accepting new Medicare assignment contracts while their billing addresses migrate to out-of-state holding companies.
Why Cardiology, Why Now
The business case for rolling up cardiology practices is straightforward: cardiology generates some of the highest revenue per physician of any outpatient specialty, driven by procedure volume that includes echocardiograms, nuclear stress tests, cardiac catheterizations, and device implantations. A single interventional cardiologist in a busy market can bill more in a year than three or four primary care physicians combined. That revenue density is exactly what PE rollup models are built to exploit – buy the practice at a multiple of EBITDA, standardize billing and contracting, then sell the consolidated platform to a larger buyer or take it public at a higher multiple.
Hospital systems have also inadvertently pushed cardiologists toward these deals. As health systems aggressively recruited cardiologists as employees through the 2010s, reimbursement for hospital-based cardiology services grew under facility fee structures. Independent cardiologists watched their reimbursement rates erode relative to their hospital-employed counterparts without access to those facility fees. For a group that has spent fifteen years building an independent practice, a PE offer representing eight to twelve times earnings can look like the only viable exit before the economics get worse.
There is a generational dimension to this, too. The founders of many regional cardiology groups are now in their late fifties and sixties. They built practices during an era when independent medicine was still financially viable and professionally autonomous. Their younger partners – often carrying significant student debt and less attached to ownership – may not want to buy them out at valuations that reflect decades of patient relationships and referral networks. PE buyers step into that succession gap with cash that neither the junior partners nor the hospital recruiters can match.
What the Deal Structure Actually Looks Like
Most PE rollups in cardiology operate through a management services organization, or MSO, structure. The physicians technically retain ownership of the professional medical entity – the PC or PLLC that employs them clinically – while the PE-backed MSO acquires the non-clinical assets: the real estate leases, equipment, billing infrastructure, and management contracts. This structure exists primarily to navigate state corporate practice of medicine laws, which prohibit non-physicians from owning medical practices outright in most states. The practical effect, however, is that the MSO controls cash flow, contracting, and operational decisions while the physicians retain liability and clinical responsibility.
Physicians entering these arrangements frequently discover, post-close, that the autonomy they were promised during the courtship period is substantially narrower than the contract language implied. Staffing decisions, vendor relationships, scheduling templates, and payer negotiations all migrate to the MSO within the first year. This pattern is well-documented in physician advocacy literature and has drawn attention from state medical boards in several markets, though formal regulatory action has been rare. The dynamic is not unlike what happened earlier in dental practice consolidation through DSO networks, where the headline autonomy guarantees proved difficult to enforce once integration was complete.
The Risks Patients and Physicians Are Taking
The most direct risk to patients is volume pressure. PE-owned specialty practices operate under return-on-investment timelines that typically run three to seven years. Within that window, the management company needs to demonstrate EBITDA growth to justify the purchase price and attract the next buyer. The most reliable way to grow EBITDA in cardiology is to increase procedure volume and reduce operating costs. Those two goals, pursued together, create a structural incentive toward over-testing and understaffing – both of which carry real clinical consequences in a specialty where diagnostic accuracy determines whether someone gets a stent they need or one they don’t.
Physician burnout accelerates sharply in the first eighteen months after a PE acquisition. The cardiologists who sold expecting to shed administrative burden often find that the new administrative layer – MSO reporting requirements, productivity dashboards, prior authorization workflows imposed by newly negotiated payer contracts – is heavier than anything they managed as independent owners. Several cardiologists who have spoken about their experiences in medical association forums describe a specific disorientation: they sold partly to stop worrying about the business, then found themselves tracked on daily relative value unit production for the first time in their careers.
The downstream effect on community cardiology access is harder to quantify but real. When a five-physician group in a mid-sized city sells to a rollup, patient panel continuity is rarely preserved through the transition. The PE buyer may expand the practice geographically by opening satellite locations – a genuine access benefit – while simultaneously reducing appointment availability for complex cases that take longer and pay the same or less. Rural and semi-rural markets are particularly exposed, because a PE-owned group that underperforms financial projections may close satellite locations that a physician-owned group would have maintained on thinner margins for community reasons.
Regulatory scrutiny is building but slowly. The Federal Trade Commission has focused its healthcare antitrust attention primarily on hospital mergers, and PE rollups in physician specialties have largely avoided equivalent review despite producing similar market concentration effects. Several state attorneys general have opened preliminary inquiries into cardiology and anesthesia rollup activity, and the American College of Cardiology has published position papers urging members to seek independent legal counsel before signing LOIs. Whether that guidance translates into friction that actually slows deal volume is the question that will define what independent cardiology looks like in a decade.
The cardiologists most at risk of signing bad deals are those in markets where the rollup has already acquired their two or three main competitors, because at that point the negotiating leverage has already shifted – the letter of intent on the table is no longer one option among several.
